Who is Shankar Musunuri?
Dr. Shankar Musunuri M.B.A., MBA, Ph. D. is the Co-Founder, Chairman & CEO at Ocugen Inc.
Who founded Ocugen?
Shankar Musunuri Insider Information. Dr. Musunuri is a seasoned biotech veteran with more than 25 years of results-driven experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, Dr.
What does Ocugen produce?
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.
Why is OCGN stock down?
Ocugen’s OCGN stock declined 3.8% on Tuesday after the FDA placed a clinical hold on a phase II/III immuno-bridging and broadening clinical study on its COVID-19 vaccine, Covaxin.
Is OCGN a buy?
Consensus Rating The company’s average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Who makes Ocugen vaccine?
Ocugen is moving closer to bringing its COVID-19 vaccine, developed by India-based Bharat Biotech, into the United States market after the Food and Drug Administration (FDA) lifted a clinical hold on its Investigational New Drug Application for Covaxin.
Will Ocugen make Covaxin?
Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years.
What is the target price for OCGN?
Stock Price Targets
| High | $15.00 |
|---|---|
| Median | $7.00 |
| Low | $4.00 |
| Average | $8.25 |
| Current Price | $2.9700 |
Does Ocugen make Covaxin?
Who developed Covishield vaccine?
Both COVISHIELD™ (manufactured by Serum Institute of India Pvt Ltd) and COVID-19 Vaccine AstraZeneca (manufactured by AstraZeneca) are ChAdOx1 nCoV- 19 Corona Virus Vaccines (Recombinant).